FutureChem Reports 25% Sales Growth in Q1, Anticipates Strong Contribution from New Drug Sales in Second Half

FutureChem is continuing its trend of improved profitability alongside sales growth in the first quarter of this year, raising expectations for increased sales of new radiopharmaceuticals in the second half of the year.

According to FutureChem on May 15, 2026, its consolidated sales for the first quarter amounted to approximately 6.4 billion won, representing a 25.3% increase compared to the 5.1 billion won recorded during the same period last year.

Profitability indicators also improved. As a result of more efficient cost of sales management, gross profit jumped by 85% year-on-year to around 1.6 billion won. Financial expenses also decreased by about 78%, leading to reductions in both operating loss and net loss by approximately 17% and 16%, respectively.

The company attributed this performance improvement to the stable expansion of sales in its existing diagnostic radiopharmaceutical product lineup and to enhanced cost structure efficiency. It explained that increased demand for major products, together with improved efficiency in production and cost management, led to simultaneous sales growth and profitability recovery.

FutureChem assessed that it has now entered a phase of strengthening its commercialization base, moving beyond a purely research and development-focused structure. While its existing product lineup continues to generate stable cash flow, the approval and market entry of new pipelines are becoming visible, which is expected to expand the foundation for medium- to long-term growth.

This trend is also linked to the company’s acquisition of regulatory approval for the prostate cancer diagnostic radiopharmaceutical Prosterview from the Ministry of Food and Drug Safety on May 1.

Prosterview targets prostate-specific membrane antigen (PSMA) and is characterized by its ability to detect microlesions and distant metastatic cancer cells with greater precision than conventional imaging diagnostics. In clinical trials, it recorded a positive predictive value (PPV) of 86.96%.

With this latest approval, FutureChem has secured its fourth core diagnostic radiopharmaceutical lineup, following drugs for the diagnosis of Parkinson’s disease and Alzheimer’s disease.

A company representative stated, “The first quarter results reflect the stable increase in demand for our existing product lineup and the effects of cost efficiency,” and added, “As our business structure shifts from research and development to a stronger commercialization base, business performance stability is also improving.”

The representative further commented, “With the approval of Prosterview, we expect new sales contributions to begin in earnest starting in the second half of this year.”

This performance is regarded as evidence that FutureChem is entering a full-fledged growth phase by simultaneously strengthening the stability of its existing diagnostic radiopharmaceutical business and the commercialization of new pipelines.

This content was produced with the assistance of AI translation services.